Saturday evening, December 11, at 6:30 p.m., ASH invites all interested meeting attendees to the Omni Hotel at CNN Center, Grand Ballroom Foyer, for the Promoting Minorities in Hematology Presentations and Reception. This event will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. One of the many highlights of the event will be the scientific presentations from the 2021 ASH Minority Medical Student Award Program and ASH Minority Resident Hematology Award Program participants.
The reception will feature poster presentations by students participating in the minority research supplement programs sponsored by the National Institutes of Health (NIH), and will also include the announcement of the 2021 ASH-Harold Amos Medical Faculty Development Program (ASH-AMFDP) award winner. Representatives from NIH will be available to provide information about their training and research offerings.
The ASH-AMFDP award program is a partnership between ASH and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Please join us this evening at the Marriott Marquis San Diego Marina to hear the impressive research presentations and to learn more about these enriching opportunities. The event will conclude with a dinner and networking session. The 2020 ASH-AMFDP winners are Emilio Ramos, MD, PhD, of University of California, San Francisco, and Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute.
Dr. Ramos (left), a hematopathology fellow, will lead a collaborative project between two institutions to use unique technologies such as cell surface proteomics and a fully in vitro antibody discovery system to determine new targets for immunotherapy and drive development of new immunotherapies that can treat blast phase myeloproliferative neoplasms (MPN-BP), a rare form of acute leukemia associated with poor prognosis.
Dr. Weeks (right), a fellow in hematology, has embarked on a research project that aims to identify novel clinical and genomic predictors of high-risk clonal hematopoiesis (CHIP), a condition associated with increased risk of developing a hematologic malignancy and to use CHIP as a biomarker to develop innovative screening and prevention strategies for individuals at risk of developing hematologic malignancies such as acute myeloid leukemia.